Potential for additional government spending on HIV/AIDS in 137 low-income and middle-income countries: an economic modelling study

被引:34
|
作者
Haakenstad, Annie [1 ]
Moses, Mark W. [2 ]
Tao, Tianchan [2 ]
Tsakalos, Golsum [2 ]
Zlavog, Bianca [2 ]
Kates, Jennifer [3 ]
Wexler, Adam [3 ]
Murray, Christopher J. L. [2 ]
Dieleman, Joseph L. [2 ]
机构
[1] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA
[2] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA
[3] Kaiser Family Fdn, San Francisco, CA USA
来源
LANCET HIV | 2019年 / 6卷 / 06期
基金
比尔及梅琳达.盖茨基金会;
关键词
SYSTEMATIC ANALYSIS; GLOBAL BURDEN; HEALTH; DISEASE;
D O I
10.1016/S2352-3018(19)30038-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Between 2012 and 2016, development assistance for HIV/AIDS decreased by 20.0%; domestic financing is therefore critical to sustaining the response to HIV/AIDS. To understand whether domestic resources could fill the financing gaps created by declines in development assistance, we aimed to track spending on HIV/AIDS and estimated the potential for governments to devote additional domestic funds to HIV/AIDS. Methods We extracted 8589 datapoints reporting spending on HIV/AIDS. We used spatiotemporal Gaussian process regression to estimate a complete time series of spending by domestic sources (government, prepaid private, and out-of-pocket) and spending category (prevention, and care and treatment) from 2000 to 2016 for 137 low-income and middle-income countries (LMICs). Development assistance data for HIV/AIDS were from Financing Global Health 2018, and HIV/AIDS prevalence, incidence, and mortality were from the Global Burden of Disease study 2017. We used stochastic frontier analysis to estimate potential additional government spending on HIV/AIDS, which was conditional on the current government health budget and other finance, economic, and contextual factors associated with HIV/AIDS spending. All spending estimates were reported in 2018 US$. Findings Between 2000 and 2016, total spending on HIV/AIDS in LMICs increased from $4.0 billion (95% uncertainty interval 2.9-6.0) to $19.9 billion (15.8-26.3), spending on HIV/AIDS prevention increased from $596 million (258 million to 1.3 billion) to $3.0 billion (1.5-5.8), and spending on HIV/AIDS care and treatment increased from $1.1 billion (458.1 million to 2.2 billion) to $7.2 billion (4.3-11.8). Over this time period, the share of resources sourced from development assistance increased from 33.2% (21.3-45.0) to 46.0% (34.2-57.0). Care and treatment spending per year on antiretroviral therapy varied across countries, with an IQR of $284-2915. An additional $12.1 billion (8.4-17.5) globally could be mobilised by governments of LMICs to finance the response to HIV/AIDS. Most of these potential resources are concentrated in ten middle-income countries (Argentina, China, Colombia, India, Indonesia, Mexico, Nigeria, Russia, South Africa, and Vietnam). Interpretation Some governments could mobilise more domestic resources to fight HIV/AIDS, which could free up additional development assistance for many countries without this ability, including many low-income, high-prevalence countries. However, a large gap exists between available financing and the funding needed to achieve global HIV/AIDS goals, and sustained and coordinated effort across international and domestic development partners is required to end AIDS by 2030. Copyright (C) 2019 The Author(s). Published by Elsevier Ltd.
引用
收藏
页码:E382 / E395
页数:14
相关论文
共 50 条
  • [1] HIV in prison in low-income and middle-income countries
    Dolan, Kate
    Kite, Ben
    Black, Emma
    Aceijas, Carmen
    Stimson, Gerry V.
    LANCET INFECTIOUS DISEASES, 2007, 7 (01): : 32 - 41
  • [2] Financing the Response to HIV in Low-Income and Middle-Income Countries
    Izazola-Licea, Jose Antonio
    Wiegelmann, Jan
    Aran, Christian
    Guthrie, Teresa
    De Lay, Paul
    Avila-Figueroa, Carlos
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 52 : S119 - S126
  • [3] HIV drug resistance in low-income and middle-income countries
    Hamers, Raph L.
    de Wit, Tobias F. Rinke
    Holmes, Charles B.
    LANCET HIV, 2018, 5 (10): : E588 - E596
  • [4] Smoking status and HIV in low-income and middle-income countries
    Jaquet, Antoine
    Dabis, Francois
    LANCET GLOBAL HEALTH, 2017, 5 (06): : E557 - E558
  • [5] Does Social Spending Improve Welfare in Low-income and Middle-income Countries?
    Haile, Fiseha
    Nino-Zarazua, Miguel
    JOURNAL OF INTERNATIONAL DEVELOPMENT, 2018, 30 (03) : 367 - 398
  • [6] Brucellosis in low-income and middle-income countries
    Rubach, Matthew P.
    Halliday, Jo E. B.
    Cleaveland, Sarah
    Crump, John A.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2013, 26 (05) : 404 - 412
  • [7] Anaemia in low-income and middle-income countries
    Balarajan, Yarlini
    Ramakrishnan, Usha
    Oezaltin, Emre
    Shankar, Anuraj H.
    Subramanian, S. V.
    LANCET, 2011, 378 (9809): : 2123 - 2135
  • [8] Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study
    Hogan, Alexandra B.
    Jewell, Britta L.
    Sherrard-Smith, Ellie
    Vesga, Juan F.
    Watson, Oliver J.
    Whittaker, Charles
    Hamlet, Arran
    Smith, Jennifer A.
    Winskill, Peter
    Verity, Robert
    Baguelin, Marc
    Lees, John A.
    Whittles, Lilith K.
    Ainslie, Kylie E. C.
    Bhatt, Samir
    Boonyasiri, Adhiratha
    Brazeau, Nicholas F.
    Cattarino, Lorenzo
    Cooper, Laura, V
    Coupland, Helen
    Cuomo-Dannenburg, Gina
    Dighe, Amy
    Djaafara, Bimandra A.
    Donnelly, Christl A.
    Eaton, Jeff W.
    van Elsland, Sabine L.
    FitzJohn, Richard G.
    Fu, Han
    Gaythorpe, Katy A. M.
    Green, William
    Haw, David J.
    Hayes, Sarah
    Hinsley, Wes
    Imai, Natsuko
    Laydon, Daniel J.
    Mangal, Tara D.
    Mellan, Thomas A.
    Mishra, Swapnil
    Nedjati-Gilani, Gemma
    Parag, Kris, V
    Thompson, Hayley A.
    Unwin, H. Juliette T.
    Vollmer, Michaela A. C.
    Walters, Caroline E.
    Wang, Haowei
    Wang, Yuanrong
    Xi, Xiaoyue
    Ferguson, Neil M.
    Okell, Lucy C.
    Churcher, Thomas S.
    LANCET GLOBAL HEALTH, 2020, 8 (09): : E1132 - E1141
  • [9] Integrated surveillance of HIV care in low-income and middle-income countries
    Tassie, Jean-Michel
    Bertagnolio, Silvia
    Souteyrand, Yves
    CURRENT OPINION IN HIV AND AIDS, 2011, 6 (04) : 233 - 238
  • [10] Conditional economic incentives to improve HIV prevention and treatment in low-income and middle-income countries
    Galarraga, Omar
    Sosa-Rubi, Sandra G.
    LANCET HIV, 2019, 6 (10): : E705 - E714